Background- Aurobindo's US subsidiary had entered into an agreement in September, 2018 to acquire Sandoz's dermatology and oral solid businesses in the US for a cash consideration of US$900 million. The acquired business was supposed to comprise 1) portfolio of dermatology, oral solids, 2) authorised generics, in-licensed products, branded dermatology products, 3) three manufacturing facilities at Hicksville - NY (Derma), Melville NY (Derma), Wilson - NC (OSD) besides entire holding in Eon Labs Inc, a wholly owned subsidiary of Sandoz. Net sales of the proposed acquired business...